tranexamic acid and Angioneurotic Edema
tranexamic acid has been researched along with Angioneurotic Edema in 74 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Ten patients with frequent attacks of non-hereditary angioedema were treated with tranexamic acid or placebo in a double blind manner, each period lasting 3 months." | 9.05 | Non-hereditary angioedema treated with tranexamic acid. A 6-month placebo controlled trial with follow-up 4 years later. ( Munch, EP; Weeke, B, 1985) |
"Tranexamic acid is an easily accessible and affordable therapy that may provide effective treatment for ACE inhibitor-induced episodes of angioedema." | 7.88 | [Tranexamic acid as first-line emergency treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors]. ( Beauchêne, C; Denis, D; Maillard, H; Martin, L; Martins-Héricher, J, 2018) |
"Prophylactic treatment with antifibrinolytic agents, epsilon-aminocaproic and tranexamic acid, reduces the incidence and severity of attacks in patients with hereditary angioedema." | 7.66 | Hepatic function and fibrinolysis in patients with hereditary angioedema undergoing long-term treatment with tranexamic acid. ( Agostoni, A; Cicardi, M; Marasini, B; Martignoni, G; Pietrogrande, M; Uziel, L, 1978) |
"Six out of 7 Finnish patients suffering from hereditary angioneurotic edema were helped during attacks, by treatment with tranexamic acid (AMCA, Cyklokapron, Kabi) in doses of 1." | 7.65 | Treatment of hereditary angioneurotic edema with tranexamic acid and cinnarizine. ( Ohela, K, 1976) |
"The five members with hereditary angioneurotic edema showed: decreased values of total hemolytic activity (CH50), deficit of C4 (between 8 and 23 percent of the normal value), and normal levels of C3 and C9." | 6.65 | [Hereditary angioneurotic edema: study of serum complement and therapeutic trial with tranexamic acid (author's transl)]. ( Gallart, MT; González, JA; Martí, I; Rodrigo, MJ, 1980) |
"Tranexamic acid (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein." | 5.72 | Tranexamic acid use in the setting of ACE inhibitor induced angioedema. ( Cox, C; Matusz, E; Stoldt, J, 2022) |
"Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation." | 5.62 | Tranexamic acid for ACE inhibitor induced angioedema. ( Geiger, H; McMahon, A; Wang, K, 2021) |
"Tranexamic acid appears to be a reasonable adjunct for the emergency medicine clinician to consider in the management of many hemorrhagic conditions and angiotensin converting enzyme inhibitor-induced angioedema." | 5.22 | Tranexamic acid - A narrative review for the emergency medicine clinician. ( Santiago, R; Wang, K, 2022) |
"Tranexamic acid (TA) is an antifibrinolytic agent, increasingly recognized as being of utility for a wide variety of skin diseases." | 5.05 | The emerging importance of tranexamic acid in dermatology. ( Al-Niaimi, F; Ali, FR; Forbat, E, 2020) |
"Acquired angioedema with C1-inhibitor deficiency is a rare and peculiar entity belonging to the spectrum of bradykinin angioedemas." | 5.05 | [Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment]. ( Armengol, G; Boccon-Gibod, I; Bouillet, L; Coppo, P; Defendi, F; Du-Thanh, A; Fain, O; Gobert, D; Hardy, G; Javaud, N; Jeandel, PY; Launay, D; Panayotopoulos, V; Pelletier, F, 2020) |
"Ten patients with frequent attacks of non-hereditary angioedema were treated with tranexamic acid or placebo in a double blind manner, each period lasting 3 months." | 5.05 | Non-hereditary angioedema treated with tranexamic acid. A 6-month placebo controlled trial with follow-up 4 years later. ( Munch, EP; Weeke, B, 1985) |
"Non-hereditary angioedema (AE) with normal C1 esterase inhibitor (C1INH) can be presumably bradykinin- or mast cell-mediated, or of unknown cause." | 4.98 | Efficacy of Treatment of Non-hereditary Angioedema. ( Blankestijn, MA; Go, MFCL; Knulst, AC; Otten, HG; van den Elzen, M; van Os-Medendorp, H, 2018) |
" A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
"Tranexamic acid is an easily accessible and affordable therapy that may provide effective treatment for ACE inhibitor-induced episodes of angioedema." | 3.88 | [Tranexamic acid as first-line emergency treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors]. ( Beauchêne, C; Denis, D; Maillard, H; Martin, L; Martins-Héricher, J, 2018) |
"Although there are no approved treatments for idiopathic angioedema, several medications used for the treatment of hereditary angioedema, such as bradykinin receptor antagonists (icatibant), kallikrein inhibitors (ecallantide), and C1 inhibitors, were successful in 10 patients." | 3.81 | Current treatment options for idiopathic angioedema. ( Hanson, J; Portnoy, J; Shroba, J, 2015) |
"When a non-histaminergic angioedema is suspected, tranexamic acid must be proposed as attack's treatment and as prophylactic treatment." | 3.72 | [Non-histaminic angiodema management: diagnostic and therapeutic interest of tranexamic acid]. ( Bouillet, L; Drouet, C; Massot, C; Ponard, D, 2004) |
"We sought to describe the characteristics of a group of patients with idiopathic nonhistaminergic angioedema and their response to prophylactic treatment with tranexamic acid." | 3.70 | Idiopathic nonhistaminergic angioedema. ( Agostoni, A; Bergamaschini, L; Cicardi, M; Gioffré, D; Zingale, LC, 1999) |
" Prophylaxis against angioneurotic oedema using danazol and tranexamic acid is described and the resultant complication of mesenteric venous thrombosis reported." | 3.67 | Acquired C1 esterase inhibitor deficiency. ( Coulson, IH; Findley, IL; Gould, TR; Razis, PA, 1986) |
"Prophylactic treatment with antifibrinolytic agents, epsilon-aminocaproic and tranexamic acid, reduces the incidence and severity of attacks in patients with hereditary angioedema." | 3.66 | Hepatic function and fibrinolysis in patients with hereditary angioedema undergoing long-term treatment with tranexamic acid. ( Agostoni, A; Cicardi, M; Marasini, B; Martignoni, G; Pietrogrande, M; Uziel, L, 1978) |
"Six out of 7 Finnish patients suffering from hereditary angioneurotic edema were helped during attacks, by treatment with tranexamic acid (AMCA, Cyklokapron, Kabi) in doses of 1." | 3.65 | Treatment of hereditary angioneurotic edema with tranexamic acid and cinnarizine. ( Ohela, K, 1976) |
"The five members with hereditary angioneurotic edema showed: decreased values of total hemolytic activity (CH50), deficit of C4 (between 8 and 23 percent of the normal value), and normal levels of C3 and C9." | 2.65 | [Hereditary angioneurotic edema: study of serum complement and therapeutic trial with tranexamic acid (author's transl)]. ( Gallart, MT; González, JA; Martí, I; Rodrigo, MJ, 1980) |
"Hereditary angioneurotic edema (HAE) is an autosomal dominant disease caused by a deficiency of a complement regulatory protein, the C1INH." | 2.38 | [Clinical contribution to the problem of correlations between hereditary angioneurotic edema and pregnancy]. ( Barrile, A; Bonanno, D; Crisafi, A; Ferlazzo, B; Ferrari, U; Quattrocchi, P; Sorge, R, 1990) |
"Tranexamic acid (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein." | 1.72 | Tranexamic acid use in the setting of ACE inhibitor induced angioedema. ( Cox, C; Matusz, E; Stoldt, J, 2022) |
"Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation." | 1.62 | Tranexamic acid for ACE inhibitor induced angioedema. ( Geiger, H; McMahon, A; Wang, K, 2021) |
"We aimed to study the subgroups of hereditary angioedema with FXII mutation (FXII-HAE), unknown genetic defect (U-HAE) and idiopathic non-histaminergic acquired angioedema (InH-AAE)." | 1.42 | Characterization of patients with angioedema without wheals: the importance of F12 gene screening. ( Bafunno, V; Barca, MP; Del Giacco, SR; Firinu, D; Manconi, PE; Margaglione, M; Santacroce, R; Vecchione, G, 2015) |
"Hereditary angioneurotic edema is a dominant autosomal disease (incidence 1/150,000), whose diagnosis is crucial as this condition can lead to fatal asphyxia within minutes." | 1.33 | [Hereditary angioneurotic edema: a case report in a 3-year-old child]. ( Amiour, M; El-Hachem, C; Guillot, M; Laurent, J, 2005) |
"Hereditary angioneurotic edema results from the deficiency of C1-esterase inhibitor." | 1.31 | [Hereditary angioneurotic edema in children]. ( Farkas, H; Füst, G; Harmat, G; Varga, L; Visy, B, 2000) |
" C 1 esterase inhibitor concentrate proved highly effective in the treatment of acute attacks (the result was lacking in one patient because of too low dosage of the drug)." | 1.26 | Treatment of hereditary angioedema. ( Agostoni, A; Cicardi, M; Marasini, B; Martignoni, GC, 1978) |
Research
Studies (74)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 34 (45.95) | 18.7374 |
1990's | 9 (12.16) | 18.2507 |
2000's | 12 (16.22) | 29.6817 |
2010's | 11 (14.86) | 24.3611 |
2020's | 8 (10.81) | 2.80 |
Authors
Authors | Studies |
---|---|
Stoldt, J | 1 |
Cox, C | 1 |
Matusz, E | 1 |
Wang, K | 2 |
Santiago, R | 1 |
Wu, YH | 1 |
Tsai, KC | 1 |
Ho, MP | 1 |
Forbat, E | 1 |
Al-Niaimi, F | 1 |
Ali, FR | 1 |
Gobert, D | 1 |
Bouillet, L | 3 |
Armengol, G | 1 |
Coppo, P | 1 |
Defendi, F | 1 |
Du-Thanh, A | 2 |
Hardy, G | 1 |
Javaud, N | 1 |
Jeandel, PY | 1 |
Launay, D | 1 |
Panayotopoulos, V | 1 |
Pelletier, F | 1 |
Boccon-Gibod, I | 1 |
Fain, O | 1 |
Grewal, E | 1 |
Sutarjono, B | 1 |
Mohammed, I | 1 |
Geiger, H | 1 |
McMahon, A | 1 |
Martinez Manzano, JM | 1 |
Lo, KB | 1 |
Patarroyo-Aponte, G | 1 |
Azmaiparashvili, Z | 1 |
Beauchêne, C | 1 |
Martins-Héricher, J | 1 |
Denis, D | 1 |
Martin, L | 1 |
Maillard, H | 1 |
Magen, E | 1 |
Chikovani, T | 1 |
Mori, T | 1 |
Matsusita, H | 1 |
Takahasi, H | 1 |
Iida, H | 1 |
Kato, K | 1 |
Yukawa, T | 1 |
Fujiki, Y | 1 |
Namiki, T | 1 |
Numata, Y | 1 |
Nishio, K | 1 |
Vincent, D | 1 |
Ponard, D | 4 |
Fiorella, S | 1 |
Drouet, C | 5 |
Firinu, D | 1 |
Bafunno, V | 1 |
Vecchione, G | 1 |
Barca, MP | 1 |
Manconi, PE | 1 |
Santacroce, R | 1 |
Margaglione, M | 1 |
Del Giacco, SR | 1 |
Shroba, J | 1 |
Hanson, J | 1 |
Portnoy, J | 1 |
van den Elzen, M | 1 |
Go, MFCL | 1 |
Knulst, AC | 1 |
Blankestijn, MA | 1 |
van Os-Medendorp, H | 1 |
Otten, HG | 1 |
Edalati, K | 1 |
Roesch, MT | 1 |
Buchanan, ML | 1 |
Teeter, M | 1 |
Maberley, DA | 1 |
Raison-Peyron, N | 1 |
Guillot, B | 1 |
Nakaigawa, N | 1 |
Kamata, K | 1 |
Komatsu, R | 1 |
Ozaki, M | 1 |
Maruta, T | 1 |
Tateishi, M | 1 |
Fujie, Y | 1 |
Maruta, N | 1 |
Yamauchi, K | 1 |
Yano, T | 1 |
Kawano, T | 1 |
Tsuneyoshi, I | 1 |
Hosotte, M | 1 |
Jarlot, S | 1 |
Luyasu, S | 1 |
Kanny, G | 1 |
Farkas, H | 2 |
Harmat, G | 2 |
Füst, G | 2 |
Varga, L | 2 |
Visy, B | 2 |
Bouillet-Claveyrolas, L | 1 |
Massot, C | 2 |
Ritchie, BC | 1 |
El-Hachem, C | 1 |
Amiour, M | 1 |
Guillot, M | 1 |
Laurent, J | 1 |
Reiss, M | 1 |
Reiss, G | 1 |
Rousset, H | 1 |
Cichon, S | 1 |
Pedraz, J | 1 |
Daudén, E | 1 |
García-Diez, A | 1 |
Fiz Matías, J | 1 |
Ferrer Cerón, SM | 1 |
García Pérez, C | 1 |
Marcos Vidal, JM | 1 |
Guerrero, M | 1 |
Prieto, L | 1 |
Basomba, A | 1 |
Campos, A | 1 |
Peláez, A | 1 |
García Villalmanzo, I | 1 |
Kodama, J | 1 |
Uchida, K | 1 |
Yoshimura, S | 1 |
Katayama, Y | 1 |
Kushiro, H | 1 |
Yutani, C | 1 |
Funahashi, S | 1 |
Takamiya, O | 1 |
Matsumoto, Y | 1 |
Ando, Y | 1 |
Gross, DJ | 1 |
Gur, H | 1 |
Dunsky, EH | 1 |
Fabiani, JE | 2 |
Simkin, G | 1 |
Freed, DL | 1 |
Buisseret, PD | 1 |
Lloyd, MJ | 1 |
Pumphrey, RS | 1 |
Garretts, M | 1 |
González, JA | 1 |
Gallart, MT | 1 |
Martí, I | 1 |
Rodrigo, MJ | 1 |
Theil, PL | 1 |
Walls, RS | 1 |
Ordman, L | 1 |
Cugno, M | 1 |
Cicardi, M | 5 |
Agostoni, A | 5 |
da Costa, JT | 1 |
da Silva, JM | 1 |
Cunha, L | 1 |
Castel-Branco, MG | 1 |
Azevedo, MV | 1 |
Novoa González, J | 1 |
Pérez Losada, AJ | 1 |
García Burriel, JI | 1 |
Jordano Montenegro, J | 1 |
Antelo Cortizas, J | 1 |
Castelli, R | 1 |
Gardinali, M | 1 |
Zingale, LC | 2 |
Savi, C | 1 |
Munari, M | 1 |
Göring, HD | 1 |
Bork, K | 1 |
Späth, PJ | 1 |
Bauer, R | 1 |
Ziemer, A | 1 |
Hintner, H | 1 |
Wüthrich, B | 1 |
Bergamaschini, L | 1 |
Gioffré, D | 1 |
Chadenat, ML | 1 |
Morelon, S | 1 |
Dupont, C | 1 |
Dorra, M | 1 |
Rouveix, E | 1 |
Ohela, K | 1 |
Davies, D | 1 |
Howell, DA | 1 |
Naish, P | 1 |
Barratt, J | 1 |
Kondo, M | 1 |
Marasini, B | 2 |
Martignoni, GC | 1 |
Spragg, J | 1 |
Laurberg, G | 2 |
Thompson, RA | 1 |
Felix-Davies, DD | 1 |
Martignoni, G | 1 |
Uziel, L | 1 |
Pietrogrande, M | 1 |
Sheffer, AL | 1 |
Fearon, DT | 1 |
Austen, KF | 1 |
Rosen, FS | 1 |
Sundin, B | 1 |
Benterud, JG | 1 |
Bosley, AR | 1 |
Zachariae, H | 1 |
Hjortshoj, A | 1 |
Casali, P | 1 |
Rugarli, C | 1 |
Zanussi, C | 1 |
Streuli, R | 1 |
Grob, P | 1 |
Frank, MM | 1 |
Gelfand, JA | 1 |
Atkinson, JP | 1 |
Danieli, R | 1 |
Pesce, M | 1 |
Vizzoni, L | 1 |
Birgerson, L | 1 |
Ferlazzo, B | 1 |
Barrile, A | 1 |
Bonanno, D | 1 |
Crisafi, A | 1 |
Ferrari, U | 1 |
Quattrocchi, P | 1 |
Sorge, R | 1 |
Verstraete, M | 1 |
Richardson, SG | 1 |
Clarke, CW | 1 |
Gasson, GB | 1 |
Håkansson, OM | 1 |
Crosher, R | 1 |
Razis, PA | 1 |
Coulson, IH | 1 |
Gould, TR | 1 |
Findley, IL | 1 |
Munch, EP | 1 |
Weeke, B | 1 |
Simkin, GO | 1 |
Leoni, J | 1 |
Squiquera, L | 1 |
Mathov, E | 1 |
Jones, L | 1 |
Bubel, MA | 1 |
Newland, AC | 1 |
Klepper, KE | 1 |
Gahlen, W | 1 |
Clinical Trials (4)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department[NCT06096077] | 50 participants (Actual) | Observational | 2022-11-30 | Completed | |||
Adaptative Servoventilation Compliance in Left Ventricular Dysfunction Patients With Central Sleep Apnea: Benefit of One Month Hypnotic (Zopiclone) Versus Placebo[NCT02820441] | Phase 4 | 2 participants (Actual) | Interventional | 2016-05-31 | Terminated | ||
[NCT02854397] | 31 participants (Actual) | Observational | 2016-02-15 | Terminated (stopped due to Recruitment difficulties) | |||
Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
12 reviews available for tranexamic acid and Angioneurotic Edema
Article | Year |
---|---|
Tranexamic acid - A narrative review for the emergency medicine clinician.
Topics: Angioedema; Antifibrinolytic Agents; Emergency Medicine; Gastrointestinal Hemorrhage; Humans; Tranex | 2022 |
The emerging importance of tranexamic acid in dermatology.
Topics: Angioedema; Antifibrinolytic Agents; Dermatology; Hemorrhage; Humans; Melanosis; Pigmentation Disord | 2020 |
[Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment].
Topics: Angioedema; Angioedemas, Hereditary; Bradykinin; Chemoprevention; Comorbidity; Diagnosis, Differenti | 2020 |
Efficacy of Treatment of Non-hereditary Angioedema.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Humans; Omalizumab; Progestins; Tr | 2018 |
[Quincke's oedema or angioedema].
Topics: Angioedema; Antifibrinolytic Agents; Bradykinin; Contraindications; Danazol; Estrogen Antagonists; H | 2012 |
Clinical management of hereditary angio-oedema in children.
Topics: Adolescent; Aminocaproic Acid; Angioedema; Child; Child, Preschool; Complement C1 Inactivator Protei | 2002 |
Protease inhibitors in the treatment of hereditary angioedema.
Topics: Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Clinical Trials as Topic; Complem | 2003 |
[Angioedema. Cause, clinical presentation, diagnosis and treatment].
Topics: Angioedema; Antifibrinolytic Agents; Glucocorticoids; Humans; Hypersensitivity; Tranexamic Acid | 2007 |
[Practical management of C1 inhibitor deficiency].
Topics: Adolescent; Adult; Aminocaproic Acid; Angioedema; Bradykinin; Child; Child, Preschool; Complement C1 | 2007 |
[Correlation of complement system with coagulation, fibrinolysis, and kinin generation].
Topics: Adult; Aminocaproates; Angioedema; Animals; Antigen-Antibody Complex; Antigen-Antibody Reactions; Bl | 1976 |
[Clinical contribution to the problem of correlations between hereditary angioneurotic edema and pregnancy].
Topics: Adult; Angioedema; Contraindications; Female; Humans; Infant, Newborn; Pedigree; Pregnancy; Pregnanc | 1990 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
Trials
3 trials available for tranexamic acid and Angioneurotic Edema
Article | Year |
---|---|
[Hereditary angioneurotic edema: study of serum complement and therapeutic trial with tranexamic acid (author's transl)].
Topics: Angioedema; Child; Clinical Trials as Topic; Complement System Proteins; Cyclohexanecarboxylic Acids | 1980 |
Menstruation-related angioedema treated with tranexamic acid.
Topics: Adult; Angioedema; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Humans; Menstruati | 1988 |
Non-hereditary angioedema treated with tranexamic acid. A 6-month placebo controlled trial with follow-up 4 years later.
Topics: Adult; Aged; Angioedema; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Diarrhea; Digestive | 1985 |
Other Studies
59 other studies available for tranexamic acid and Angioneurotic Edema
Article | Year |
---|---|
Tranexamic acid use in the setting of ACE inhibitor induced angioedema.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Humans; Kallikreins; Tranexamic Ac | 2022 |
Tranexamic acid use for ACE inhibitor induced angioedema.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Humans; Tranexamic Acid | 2022 |
Angioedema, ACE inhibitor and COVID-19.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Anti-Allergic Agents; Benzazepines; Betacorona | 2020 |
Tranexamic acid for ACE inhibitor induced angioedema.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Antifibrinolytic Agents; Female; Humans; Lisin | 2021 |
The use of intravenous tranexamic acid for patients with angiotensin-converting enzyme inhibitor-induced angioedema: A case series.
Topics: Administration, Intravenous; Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Antifibrino | 2021 |
[Tranexamic acid as first-line emergency treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors].
Topics: Adult; Aged; Aged, 80 and over; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Em | 2018 |
Development of angio-oedema after omalizumab injections in a patient with chronic spontaneous urticaria.
Topics: Adult; Angioedema; Anti-Allergic Agents; Antifibrinolytic Agents; Chronic Disease; Female; Humans; I | 2018 |
[Case report; a case of hereditary angioedema with laryngeal edema leading to suffocation].
Topics: Airway Management; Angioedema; Antifibrinolytic Agents; Asphyxia; Bronchoscopy; Complement C1 Inhibi | 2013 |
Benefits of hydroxychloroquine in the treatment of a patient with angioedema due to acquired C1 inhibitor deficiency.
Topics: Aged; Angioedema; Angioedemas, Hereditary; Antibodies, Blocking; Autoantibodies; Autoimmunity; Compl | 2015 |
Characterization of patients with angioedema without wheals: the importance of F12 gene screening.
Topics: Adolescent; Adult; Aged; Angioedema; Angioedemas, Hereditary; Antifibrinolytic Agents; Bradykinin; B | 2015 |
Current treatment options for idiopathic angioedema.
Topics: Adolescent; Angioedema; Antibodies, Anti-Idiotypic; Bradykinin; Female; Humans; Peptides; Tranexamic | 2015 |
Central serous chorioretinopathy and idiopathic nonhistaminergic angioedema.
Topics: Adult; Angioedema; Antifibrinolytic Agents; Capillary Permeability; Choroid; Fluorescein Angiography | 2009 |
Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema.
Topics: Adolescent; Adult; Aged; Angioedema; Bradykinin; Child; Child, Preschool; Female; Humans; Infant; Ma | 2010 |
[Perioperative management of a patient complicated with Quincke's edema].
Topics: Aneurysm, Ruptured; Angioedema; Chlorpheniramine; Craniotomy; Humans; Intracranial Aneurysm; Intubat | 2010 |
[Anesthesia and perioperative management in a patient with acquired angioedema].
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Angioedema; Complement C1 Inhibitor Protein; Female; Human | 2011 |
Clinical and biological distinctions between type I and type II acquired angioedema.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Autoantibodies; Complement C1 Inactivator Prot | 2003 |
[Non-histaminic angiodema management: diagnostic and therapeutic interest of tranexamic acid].
Topics: Adolescent; Adult; Angioedema; Female; Humans; Male; Tranexamic Acid | 2004 |
[Hereditary angioneurotic edema: a case report in a 3-year-old child].
Topics: Adrenergic Agonists; Angioedema; Anti-Inflammatory Agents; Antifibrinolytic Agents; Asthma; Child, P | 2005 |
[Hereditary angioneurotic edema: a case report in a 3-year-old child].
Topics: Adrenergic Agonists; Angioedema; Anti-Inflammatory Agents; Antifibrinolytic Agents; Asthma; Child, P | 2005 |
[Hereditary angioneurotic edema: a case report in a 3-year-old child].
Topics: Adrenergic Agonists; Angioedema; Anti-Inflammatory Agents; Antifibrinolytic Agents; Asthma; Child, P | 2005 |
[Hereditary angioneurotic edema: a case report in a 3-year-old child].
Topics: Adrenergic Agonists; Angioedema; Anti-Inflammatory Agents; Antifibrinolytic Agents; Asthma; Child, P | 2005 |
A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene.
Topics: Angioedema; Antifibrinolytic Agents; Complement C1 Inhibitor Protein; Female; Humans; Pregnancy; Pre | 2007 |
[Obstetric analgesia for a women with type III hereditary angioneurotic edema].
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Local; Angioedema; Antifibrinolytic | 2007 |
[Familial angioedema (II). Treatment].
Topics: Aminocaproic Acid; Angioedema; Cinnarizine; Complement C1 Inactivator Proteins; Danazol; Histamine H | 1984 |
Studies of four Japanese families with hereditary angioneurotic edema: simultaneous activation of plasma protease systems and exogenous triggering stimuli.
Topics: Angioedema; Coagulants; Cold Temperature; Complement C1 Inactivator Proteins; Complement System Prot | 1984 |
[Hereditary angio-edema].
Topics: Adult; Angioedema; Child; Complement C1 Inactivator Proteins; Danazol; Female; Humans; Tranexamic Ac | 1984 |
[Familial hereditary angioedema].
Topics: Adult; Angioedema; Complement C1 Inactivator Proteins; Female; Humans; Tranexamic Acid | 1983 |
Angioedema responding to antiprotease treatment but without abnormalities of the complement system.
Topics: Adult; Aminocaproates; Angioedema; Blood Coagulation Tests; Complement C1; Complement C3; Complement | 1980 |
Ophthalmological examination of patients in long-term treatment with tranexamic acid.
Topics: Adolescent; Adult; Aged; Angioedema; Color Perception Tests; Cornea; Cyclohexanecarboxylic Acids; Fe | 1981 |
Clinical presentation and diagnosis of hereditary angio-oedema in five families.
Topics: Adult; Angioedema; Complement C1 Inactivator Proteins; Complement System Proteins; Female; Humans; M | 1981 |
Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid.
Topics: Acute Disease; Aged; Angioedema; Autoantibodies; Autoimmune Diseases; Complement C1 Inactivator Prot | 1994 |
Hereditary angioedema presenting with adult respiratory distress syndrome.
Topics: Adult; Angioedema; Complement C1 Inactivator Proteins; Danazol; Humans; Laryngeal Edema; Male; Respi | 1994 |
[Hereditary angioedema. Diagnosis and treatment during childhood].
Topics: Age Factors; Angioedema; Child, Preschool; Complement C1 Inactivator Proteins; Female; Humans; Trane | 1993 |
Cardiopulmonary by-pass in a patient with acquired C1 inhibitor deficiency.
Topics: Aged; Anabolic Agents; Angioedema; Antifibrinolytic Agents; Aprotinin; Autoimmune Diseases; Calcium | 1997 |
[Hereditary angioedema in the German-speaking region].
Topics: Adolescent; Adult; Angioedema; Child; Child, Preschool; Complement C1 Inactivator Proteins; Danazol; | 1998 |
Idiopathic nonhistaminergic angioedema.
Topics: Adolescent; Adult; Aged; Angioedema; Antifibrinolytic Agents; Complement System Proteins; Female; Hi | 1999 |
[Acquired angioneurotic edema: association with hydatidosis].
Topics: Angioedema; Antifibrinolytic Agents; Danazol; Echinococcosis; Estrogen Antagonists; Follow-Up Studie | 2000 |
[Hereditary angioneurotic edema in children].
Topics: Adolescent; Angioedema; Child; Child, Preschool; Complement C1 Inactivator Proteins; Danazol; Diagno | 2000 |
Treatment of hereditary angioneurotic edema with tranexamic acid and cinnarizine.
Topics: Adult; Aged; Angioedema; Cyclohexanecarboxylic Acids; Fatigue; Female; Follow-Up Studies; Humans; Ma | 1976 |
Tranexamic acid and arterial thrombosis.
Topics: Adult; Angioedema; Arteritis; Carotid Artery Thrombosis; Cyclohexanecarboxylic Acids; Female; Humans | 1977 |
Hereditary angiooedema.
Topics: Adult; Age Factors; Aged; Angioedema; Danazol; Female; Humans; Male; Middle Aged; Pregnancy; Pregnan | 1979 |
Treatment of hereditary angioedema.
Topics: Adolescent; Adult; Aged; Angioedema; Aprotinin; Child; Complement C1 Inactivator Proteins; Female; H | 1978 |
Specific functional and immunologic assay of plasma plasminogen in hereditary angioedema, in hereditary angioedema treated with tranexamic acid, and in normal subjects.
Topics: Angioedema; Antigens; Cyclohexanecarboxylic Acids; Humans; Plasminogen; Tranexamic Acid | 1978 |
Plasma kinin activation in tranexamic acid treated patients with hereditary angioneurotic edema.
Topics: Adult; Aged; Angioedema; Cyclohexanecarboxylic Acids; Factor XII; Female; Humans; Kinins; Male; Midd | 1978 |
Response of "idiopathic" recurrent angioneurotic oedema to tranexamic acid.
Topics: Adult; Angioedema; Cyclohexanecarboxylic Acids; Female; Humans; Recurrence; Tranexamic Acid | 1978 |
Hepatic function and fibrinolysis in patients with hereditary angioedema undergoing long-term treatment with tranexamic acid.
Topics: Adolescent; Adult; Alanine Transaminase; Angioedema; Aspartate Aminotransferases; Bilirubin; Child; | 1978 |
Tranexamic acid: preoperative prophylactic therapy for patients with hereditary angioneurotic edema.
Topics: Adolescent; Adult; Angioedema; Cyclohexanecarboxylic Acids; Gastrectomy; Humans; Hysterectomy; Middl | 1977 |
[A case of non-hereditary angioneurotic edema treated with tranexamic acid].
Topics: Angioedema; Cyclohexanecarboxylic Acids; Female; Humans; Middle Aged; Tranexamic Acid | 1977 |
[Hereditary angioneurotic edema].
Topics: Angioedema; Child; Child, Preschool; Female; Humans; Male; Prognosis; Tranexamic Acid | 1976 |
Familial anglo-oedema--a particularly severe form.
Topics: Adult; Angioedema; Complement C1 Inactivator Proteins; Humans; Male; Pedigree; Tranexamic Acid | 1976 |
[Tranexamic acid (Cyclokapron) in hereditary angioneurotic edema].
Topics: Adolescent; Adult; Aged; Angioedema; Child; Cyclohexanecarboxylic Acids; Female; Humans; Male; Middl | 1975 |
A study of complement functions in a family with hereditary angioneurotic edema.
Topics: Adolescent; Adult; Angioedema; Complement C1; Complement C3; Complement System Proteins; Enzyme Inhi | 1975 |
[Study of a large family with hereditary angioneurotic edema].
Topics: Adolescent; Adult; Aged; Angioedema; Complement C1; Complement C3; Complement Inactivator Proteins; | 1975 |
Hereditary angioedema: the clinical syndrome and its management.
Topics: Adolescent; Adult; Aged; Aminocaproates; Angioedema; Blood Transfusion; Child; Complement Inactivato | 1976 |
[Hereditary angioedema. Description of a pediatric case].
Topics: Angioedema; Child, Preschool; Esterases; Humans; Male; Tranexamic Acid | 1991 |
Tranexamic acid in the treatment of hereditary angioedema.
Topics: Angioedema; Drug and Narcotic Control; Humans; Tranexamic Acid; United States; United States Food an | 1991 |
Lymphocytic lymphoma and acquired C1 esterase inhibitor deficiency.
Topics: Angioedema; Complement C1 Inactivator Proteins; Complement C3; Complement C4; Female; Humans; Leukem | 1989 |
Intravenous tranexamic acid in the management of hereditary angio-oedema.
Topics: Administration, Oral; Adolescent; Adult; Angioedema; Cyclohexanecarboxylic Acids; Diseases in Twins; | 1987 |
Acquired C1 esterase inhibitor deficiency.
Topics: Angioedema; Complement C1 Inactivator Proteins; Female; Humans; Mesenteric Vascular Occlusion; Middl | 1986 |
Hereditary angioedema: polymorphism.
Topics: Adolescent; Adult; Aminocaproates; Angioedema; Danazol; Female; Humans; Levamisole; Male; Polymorphi | 1985 |
C1 esterase inhibitor as a possible tumour marker in malignant lymphoma.
Topics: Angioedema; Chlorambucil; Chlorpheniramine; Complement C1 Inactivator Proteins; Humans; Lymphoma; Ma | 1985 |
[Hereditary angioneurotic edema].
Topics: Adult; Aged; Aminocaproates; Angioedema; Complement C1; Enzyme Inhibitors; Esterases; Female; Humans | 1974 |